Global Crohn's disease therapeutics Market Size, Share, Growth, Research and Forecast 2019-2025

Improvement in the treatment modalities for Crohn's disease has been observed in the developed economies such as the US and UK. The increased understanding of the disease followed with immunopathology is aiding the development of new targeted treatment solutions for Crohn's disease, which includes the use of stem cell treatment, as they have a capability of modulating the immune system. The use of stem cell transplants for the treatment of immune systems has found to be successful in treating Crohn's disease. Researchers at the University of Alabama at Birmingham have revealed the availability of diverse group of cells in the immune system that perpetuates and induces inflammation in the gut. These cells are CD4 T cells that could serve as an effective solution in treatment, or even in cure of Crohn's disease.

A full report of Global Crohn's disease therapeutics Market is available at: https://www.omrglobal.com/industry-reports/crohns-disease-therapeutics-market

European Commission has approved the use of Alofisel for the treatment of perianal fistulas in patients dealing with luminal Crohn's disease, and the one who have shown inadequate response to conventional or biologic therapy. Alofisel is the first allogeneic stem cell therapy that has received marketing authorization in Europe. The FDA issued orphan drug designation for the treatment of IBD through Alofisel in 2017. Moreover, Takeda Pharmaceuticals announced the acquisition of TiGenix in March 2018, by offering a sum of over $591 million. Through the acquisition, Takeda has received the right to develop and market Alofisel outside the US. Researchers at Wake Forest Institute for Regenerative Medicine (WFIRM) are practicing the induction of stem cells in the development of an injectable cell therapy that can advance the treatment of Crohn's disease. This is anticipated to mark the advancement of stem cell therapy in the Crohn's disease treatment that further propels the market growth.

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/crohns-disease-therapeutics-market

Mergers, acquisition, and partnerships are likely to spur the Crohn's disease therapeutics market growth

Numerous market participants across the globe are adopting the strategy of mergers and acquisitions to gain a market share. In line with this strategy Johnson & Johnson Services, Inc. in February 2018 collaborated with Theravance Biopharma so as to commercialize IBD treatment products. Moreover, in November 2018, the company also collaborated with Vedanta Biosciences for the development of bacteria-based treatment of IBD. The above developments were in line with the strategy of the company to expand its product portfolio and capabilities so as to cater to the demand of customers. Furthermore, companies are also emphasizing on the expansion of its footprints across the globe. For instance, in 2016, UCB, Inc. collaborated with Astellas, a Japanese company, to expand its footprints in Japan. The company aims at developing treatment of Crohn's disease in Japan.

Global Crohn's disease therapeutics Market Segmentation

By Treatment Type

o Surgery
o Anti- Inflammatory Drug Administration

For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/crohns-disease-therapeutics-market

Global Crohn's disease therapeutics Market - Segment by Region

North America

o United States
o Canada

Europe

o Germany
o United Kingdom
o France
o Spain
o Italy
o Rest of Europe

Asia-Pacific

o China
o Japan
o India
o Rest of Asia-Pacific

Rest of the World

Company Profiles

o Abbott Laboratories
o AbbVie Inc.
o Allergan, PLC
o Boehringer Ingelheim International GmbH
o Celgene Corp.
o Daiichi Sankyo Co. Ltd.
o Eli Lilly and Co.
o F. Hoffmann-La Roche AG
o GlaxoSmithKline PLC
o Johnson & Johnson Services Inc.
o Laboratory Corporation of America Holdings
o Mercator Pharmaceutical Solutions
o Pfizer Inc.
o Pharmacosmos A/S
o RPG Life Sciences Ltd.
o Sanofi S.A.
o Takeda pharmaceutical Co., Ltd.
o UCB, Inc.
o Vifor Pharma Group

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +1 646-755-7667, +91 7803040404

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.